Skip to main content

Table 4 Comparison of the microbiological characteristics with monomicrobial SA-BSI and polymicrobial SA-BSI

From: Clinical characteristics and risk factors of polymicrobial Staphylococcus aureus bloodstream infections

 Total
(n = 349)
Mono-SA-BSI
(n = 295)
Poly-SA-BSI
(n = 54)
p-value
Source of BSIs
 Pneumonia93 (26.6%)69 (23.4%)24 (44.4%)0.00
  Hospital-acquired pneumonia69 (74.2%)47 (68.1%)22 (91.7%)0.02
  Community-acquired pneumonia24 (25.8%)22 (31.9%)2 (8.3%)
 Skin and Soft tissue infection86 (24.6%)69 (23.4%)16 (29.6%)0.33
 Central venous catheter65 (18.6%)61 (20.7%)4 (7.4%)0.04
 Intra-abdominal42 (12%)34 (11.5%)8 (14.8%)0.50
 Primary BSI28 (7.7%)27 (9.2%)1 (1.9%)0.10
 Bone and joint14 (4.0%)14 (4.7%)0 (0%)0.14
 Endocarditis11 (3.2%)11 (3.7%)0 (0%)0.23
 Urinary tract infection9 (2.6%)8 (2.7%)1 (1.9%)0.58
 Others*2 (0.6%)2 (0.7%)0 (0%)0.71
MRSA236 (67.6%)192 (65.1%)44 (81.5%)0.02
Delayed antibiotic therapy29 (8.3%)24 (8.1%)5 (9.3%)0.78
Antibiotic resistancea
 Cefoxitin (115 vs 25)b114 (81.4%)89 (77.4%)25 (100%)0.01
 Ciprofloxacin (237 vs 42)b132 (47.3%)96 (40.5%)36 (85.5%)0.00
 Clindamycin (295 vs 54)b127 (36.4%)110 (37.3%)17 (31.5%)0.42
 Erythromycin (295 vs 54)b203 (58.2%)167 (56.6%)36 (66.7%)0.17
 Gentamicin (295 vs 54)b58 (16.6%)50 (16.9%)8 (14.8%)0.71
 Levofloxacin (261 vs 49)b161 (51.9%)118 (45.2%)43 (87.8%)0.00
 Linezolid (293 vs 54)b46 (13.3%)37 (12.6%)9 (16.7%)0.42
 Moxifloxacin (287 vs 51)b158 (46.7%)117 (40.8%)41 (80.4%)0.00
 Nitrofurantoin (255 vs 50)b1 (0.3%)1 (0.4%)0 (0%)1
 Oxacillin (295 vs 54)b236 (67.6%)192 (65.1%)44 (81.5%)0.02
 Penicillin (295 vs 54)b333 (95.4%)279 (94.6%)54 (100%)0.08
 Quinupristin/Dalfopristin (295 vs 54)b44 (12.6%)36 (12.2%)8 (14.8%)0.60
 Rifampin (242 vs 43)b9 (3.2%)8 (3.3%)1 (2.3%)1
 Tetracycline (230 vs 50)b148 (52.9%)112 (48.7%)36 (72%)0.00
 Vancomycin (278 vs 49)b48 (14.3%)39 (13.6%)9 (18.4%)0.38
  1. *oromaxillo-facial region and prosthetic device
  2. aNot all agents listed tested in all isolates
  3. bThe numbers in parentheses represent the total numbers of Staphylococcus aureus isolates performed susceptibility test
  4. Abbreviations: BSIs Bloodstream infections, MRSA Methicillin-resistant Staphylococcus aureus, SA-BSI Staphylococcus aureus bloodstream infections